Nintedanib Ratiopharm

Nintedanib, the active ingredient in Nintedanib Ratiopharm, is a tyrosine kinase inhibitor presented as a 100 mg capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is indicated for fibrotic lung disorders and as part of combination therapy for certain lung cancers.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when combined with chemotherapy.

Nintedanib may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Decreased appetite: reduced desire to eat.

Serious or Rare Side Effects: - Elevated liver enzymes: may indicate hepatic injury. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Arterial thromboembolic events: potential for clot formation in arteries. - Gastrointestinal perforation: rare but severe tearing of the GI tract.

Before initiating therapy, several safety considerations should be addressed.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use. - Cardiovascular evaluation: screen for history of arterial thrombotic disease. - Gastrointestinal symptom counseling: advise patients to report severe abdominal pain or persistent diarrhea. - Store at below 25°C: keep in the original pack, protect from moisture.

Nintedanib can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antiplatelet agents (e.g., aspirin, clopidogrel): monitor for bleeding. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal toxicity risk.